Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2023.06.06

Commitment to Sustainability

Sai Life Sciences reaffirms commitment to Sustainability, charts out SDGs to be achieved by FY27

On the World Environment Day 2023, Sai Life Sciences, a global Contract Research, Development & Manufacturing Organization (CRO-CDMO), announced its renewed Sustainable Development Goals (SDG) charting out the roadmap to achieve specific environmental, social and governance (ESG) targets by the financial year ending March 31, 2027.

Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Our renewed Sustainable Development Goals reflect a coming of age of our Sustainability journey. The learnings and successes from the first edition have shaped our aspiration for this phase and signify a certain boldness that comes with persevering unabated on a chosen path. While Sustainability has always been at the heart of our ethos at Sai Life Sciences, I must thank all our customers and partners for inspiring us raise the bar each day.”

Sai Life Sciences first charted out its SDGs in 2019 with a three-year timeline. During this period, despite rapidly scaling up its operations, the company considerably exceeded its targets in areas such as the utilization of renewable energy, recycling of hazardous waste and reduction in greenhouse gas emissions, while making substantial progress in other areas.

Buoyed by the success and learnings from its experience, Sai Life Sciences has outlined the following SDGs to be achieved over a 5-year period, with FY22 as the baseline year:

  • Reduce specific water consumption by 25%.
  • Reduce specific greenhouse gas emissions by 30% and replace 70% of our energy requirement with renewable sources.
  • Reduce specific hazardous waste generation by 10% and recycle 90%of hazardous waste through co-processing and alternate reuse.
  • Create more opportunities for women and increase the percentage of women employees in the total workforce to 18%.
  • Advance socio-economic empowerment of women and provide education for 8,000 people from socially and less privileged communities through our CSR programs.
  • Engage with 100% of critical suppliers in committing to the code of supplier conduct and ethics.

In December 2022, Sai Life Sciences released its third Sustainability Report. The report described the company’s efforts in progressively reducing the knowing-doing gap by proactively addressing sustainability-related material issues.

Share article

More News

2026.03.27

Inside Sai Life Sciences’ Integrated R&D Campus: Accelerating Drug Development

In a recent feature published in R&D World, Sai Life Sciences’ Integrated R&D Campus in Hyderabad is showcased as a model for accelerating drug discovery and development through true scientific integration.In the article, Dr. B.V.N.B.S. Sarma, Senior Vice President – Discovery, highlights how co-locating multidisciplinary teams—from medicinal chemistry and biology to DMPK, developability, process development, […]
Read more

2026.03.27

Sai Life Sciences hosts Biotech Pitch Day 2026 at Boston Site

Sai Life Sciences successfully hosted its Biotech Pitch Day 2026 at its Boston-area site on March 19, bringing together a dynamic group of emerging biotech innovators, scientific leaders, and industry experts. The event was designed as a platform for early-stage biotech companies to showcase their science, strengthen visibility, and engage with potential collaborators across the […]
Read more

2026.03.25

Kudikunta Lake restoration completed, marking the revival of an urban water body

Kudikunta Lake in Kondapur, Hyderabad, was inaugurated on February 28th following the completion of restoration efforts undertaken by Sai Life Sciences as part of its Corporate Social Responsibility (CSR) initiative in collaboration with the Society for Advancement of Human Endeavour (SAHE). The event marked the culmination of several months of work to restore a previously […]
Read more

2026.03.10

AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery. Retrosynthesis is a […]
Read more

2026.03.10

Structural Biology capabilities launched with X-Ray Crystallography

Sai Life Sciences has introduced integrated structural biology capabilities with the establishment of X-ray protein crystallography workflows to support structure-based drug discovery programs. The platform encompasses end-to-end protein engineering capabilities, including construct design, gene synthesis, and in-house recombinant protein expression and purification. These foundational steps enable generation of high-quality protein material suitable for structural and […]
Read more